Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
3 pending office actions • 2 art units • 2 examiners • 0 of 3 (0%) have an AI response strategy ready • 2 patents granted in the last 365 days
Shear Kershman Laboratories Inc. currently has 3 pending office actions in the Biotechnology & Pharmaceuticals technology area. GONZALEZ, LUISALBERTO is the busiest examiner for this portfolio, managing 2 busiest examiner pending actions. This indicates that a specific individual is responsible for multiple pending office actions currently active.
The prosecution involves 2 distinct examiners, requiring the company to manage different sets of feedback within the Biotechnology & Pharmaceuticals sector. Because the workload is also spread across distinct art units, the company must coordinate its legal strategy to meet various administrative requirements. The focus on 3 pending office actions suggests a period of active engagement with the patent office, where the decisions of the busiest examiner will significantly impact the overall portfolio. Practitioners should prepare for detailed technical discussions within the Biotechnology & Pharmaceuticals sector.
Based on the USPTO statutory response window for each pending office action. 3 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 3 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (33%) |
| Double-patenting + other | 1 (33%) |
| Multi-statute (no §101) | 1 (33%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| GONZALEZ, LUISALBERTO | 2 | 59.4% | +47.2% |
| PETRITSCH, AMANDA MICHELLE | 1 | 57.1% | +28.1% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18090560 | Canine Antimicrobial Dental Gel | PETRITSCH, AMANDA MICHELLE | 52d overdue |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 3 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18103193 | Canine Melatonin-Containing Transmucosal Gel | GONZALEZ, LUISALBERTO | 88d overdue |
| 18600654 | Topical Antimicrobial Lotion for Treating Pyotraumatic Dermatitis Lesions | GONZALEZ, LUISALBERTO | 79d overdue |
| 18090560 | Canine Antimicrobial Dental Gel | PETRITSCH, AMANDA MICHELLE | 52d overdue |
| Art Unit | Apps |
|---|---|
| 1624 | 2 |
| 1612 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18600654 | Topical Antimicrobial Lotion for Treating Pyotraumatic Dermatitis Lesions | GONZALEZ, LUISALBERTO | 1624 | §103DP | Final Rejection | 79d overdue | Pending | Mar 09, 2024 |
| 18103193 | Canine Melatonin-Containing Transmucosal Gel | GONZALEZ, LUISALBERTO | 1624 | §103 | Final Rejection | 88d overdue | Pending | Jan 30, 2023 |
| 18090560 | Canine Antimicrobial Dental Gel | PETRITSCH, AMANDA MICHELLE | 1612 | §103§112 | Final Rejection | 52d overdue | Pending | Dec 29, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial